Covered recipient · General Payments record
JOHN ANGELO DELROSSI
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2023–2024
$733.42
- Reported across 48 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $447.65 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $261.72 | 15 |
| REVANCE THERAPEUTICS, INC. | $146.99 | 2 |
| Galderma Laboratories, L.P. | $38.94 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $51.30 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009719 | CMS |
| ABBVIE INC. | $9.64 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009721 | CMS |
| ABBVIE INC. | $3.14 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009723 | CMS |
| ABBVIE INC. | $11.71 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009725 | CMS |
| ABBVIE INC. | $4.55 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009727 | CMS |
| ABBVIE INC. | $4.07 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009729 | CMS |
| ABBVIE INC. | $16.11 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009731 | CMS |
| ABBVIE INC. | $31.12 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009733 | CMS |
| ABBVIE INC. | $16.68 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009735 | CMS |
| ABBVIE INC. | $15.59 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009737 | CMS |
| ABBVIE INC. | $16.20 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009739 | CMS |
| ABBVIE INC. | $11.98 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009741 | CMS |
| ABBVIE INC. | $14.75 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009743 | CMS |
| ABBVIE INC. | $29.95 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009745 | CMS |
| ABBVIE INC. | $24.93 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107009747 | CMS |
| Galderma Laboratories, L.P. | $38.94 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145353527 | CMS |
| REVANCE THERAPEUTICS, INC. | $102.84 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147938045 | CMS |
| REVANCE THERAPEUTICS, INC. | $44.15 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147938047 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.